IMMUSOFT
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.
IMMUSOFT
Industry:
Biotechnology Life Science Therapeutics
Founded:
2009-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.immusoft.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
41.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-03-09 | Discovery Genomics | Discovery Genomics acquired by Immusoft | N/A |
Investors List
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Immusoft
Breakout Ventures
Breakout Ventures investment in Venture Round - Immusoft
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Venture Round - Immusoft
National Institutes of Health
National Institutes of Health investment in Grant - Immusoft
Ikarian Capital
Ikarian Capital investment in Venture Round - Immusoft
Breakout Ventures
Breakout Ventures investment in Series B - Immusoft
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Immusoft
RBV Capital
RBV Capital investment in Series B - Immusoft
GRIDS Capital
GRIDS Capital investment in Series B - Immusoft
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Series B - Immusoft
Official Site Inspections
http://www.immusoft.com
- Host name: ec2-34-238-11-122.compute-1.amazonaws.com
- IP address: 34.238.11.122
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immusoft"
Immusoft - Crunchbase Company Profile & Funding
Immusoft is a biotechnology company that is commercializing technology to … See details»
Immusoft - LinkedIn
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. See details»
Immusoft 2025 Company Profile: Valuation, Funding & Investors
Immusoft General Information Description. Developer of novel therapies designed for the treatment of rare diseases. The company develops autologous cell therapies based on its immune system … See details»
Immusoft Corporation Company Profile | Seattle, WA | Competitors ...
Find company research, competitor information, contact details & financial data for Immusoft Corporation of Seattle, WA. Get the latest business insights from Dun & Bradstreet. See details»
Immusoft Company Profile - Office Locations, Competitors ... - Craft
Immusoft has 5 employees across 2 locations and $9.4 m in total funding,. See insights on Immusoft including office locations, competitors, revenue, financials, executives, subsidiaries and more at … See details»
Immusoft - VentureRadar
Immusoft Corporation's (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP?). The technology modifies a … See details»
Immusoft Pipeline - Immusoft
© IMMUSOFT 2025 | 454 N 34th St., Seattle, WA 98103 | Directions | [email protected] | [email protected] See details»
Immusoft Information - RocketReach
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a … See details»
Immusoft - 2025 Company Profile, Funding & Competitors - Tracxn
May 28, 2025 Immusoft is a series B company based in Seattle (United States), founded in 2009 by Matthew Scholz. It operates as an Autologous cell therapies based on its Immune system … See details»
Immusoft - Contacts, Employees, Board Members, Advisors & Alumni
Immusoft is a biotechnology company that develops novel cell therapies for therapeutic protein delivery for rare diseases. ... Experience the new Crunchbase, powered by AI . Experience the … See details»
Immusoft Overview | SignalHire Company Profile
Immusoft is a private company that has been in the industry for 14 years. The company currently specializes in the Biotechnology, Pharmaceuticals, Biotechnology areas. ... Organization Website: … See details»
Immusoft Awarded $8M in Funding from the California Institute for ...
Jan 27, 2023 San Francisco, CA – (BUSINESS WIRE) – January 26, 2023 — Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy … See details»
Cell therapy startup Immusoft lands deal with Takeda worth
Oct 14, 2021 Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than … See details»
Immusoft - F6S
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a … See details»
Immusoft - Funding, Financials, Valuation & Investors - Crunchbase
Immusoft is funded by 22 investors. California Institute for Regenerative Medicine and California Institute for Regenerative Medicine are the most recent investors. Immusoft has a post-money … See details»
Science - Immusoft
At Immusoft, we have successfully encoded B cells to produce enzymes, antibodies, structural proteins, and signaling proteins. Each of these protein types represents major opportunities to … See details»
About - Immusoft
Rob Hayes Chief Scientific Officer . Dr. Robert Hayes is the Chief Scientific Officer at Immusoft, where he oversees Immusoft’s preclinical research and spearheads the near-term advancement … See details»
Press Releases Archives - Immusoft
SEATTLE–(BUSINESS WIRE)– Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the … See details»
Canada's priority antimicrobial-resistant pathogens
2 days ago The World Health Organization first published its bacterial priority pathogens list in 2017, with an update in 2024, and released its fungal priority pathogens list in 2022. Building on … See details»
News - Immusoft
Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial Read More. News Articles; Citeline | February 27, … See details»